VALNEVA SE (VLA.PA)
FR0004056851 - Common Stock
VLA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 80 industry peers in the Biotechnology industry. VLA has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, VLA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
VLA had negative earnings in the past year.
VLA had a negative operating cash flow in the past year.
VLA had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: VLA reported negative operating cash flow in multiple years.
1.2 Ratios
VLA has a Return On Assets of -33.43%. This is comparable to the rest of the industry: VLA outperforms 50.67% of its industry peers.
VLA has a Return On Equity of -119.91%. This is in the lower half of the industry: VLA underperforms 61.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.43% | ||
| ROE | -119.91% | ||
| ROIC | N/A |
ROA(3y)-18.03%
ROA(5y)-13.82%
ROE(3y)-62.44%
ROE(5y)-54.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 36.83%, VLA is in line with its industry, outperforming 53.33% of the companies in the same industry.
In the last couple of years the Gross Margin of VLA has declined.
The Profit Margin and Operating Margin are not available for VLA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 36.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%
2. Health
2.1 Basic Checks
VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VLA has been increased compared to 1 year ago.
VLA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, VLA has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.17, we must say that VLA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.17, VLA perfoms like the industry average, outperforming 42.67% of the companies in the same industry.
VLA has a Debt/Equity ratio of 1.26. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.26, VLA is doing worse than 61.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.17 |
ROIC/WACCN/A
WACC8.19%
2.3 Liquidity
VLA has a Current Ratio of 1.65. This is a normal value and indicates that VLA is financially healthy and should not expect problems in meeting its short term obligations.
VLA has a Current ratio of 1.65. This is comparable to the rest of the industry: VLA outperforms 44.00% of its industry peers.
VLA has a Quick Ratio of 1.37. This is a normal value and indicates that VLA is financially healthy and should not expect problems in meeting its short term obligations.
VLA has a Quick ratio of 1.37. This is comparable to the rest of the industry: VLA outperforms 42.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
VLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.19%, which is quite impressive.
Looking at the last year, VLA shows a very negative growth in Revenue. The Revenue has decreased by -59.29% in the last year.
VLA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.34% yearly.
EPS 1Y (TTM)83.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%415.38%
Revenue 1Y (TTM)-59.29%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Sales Q2Q%-2.25%
3.2 Future
Based on estimates for the next years, VLA will show a very strong growth in Earnings Per Share. The EPS will grow by 35.23% on average per year.
Based on estimates for the next years, VLA will show a very strong growth in Revenue. The Revenue will grow by 22.69% on average per year.
EPS Next Y119.02%
EPS Next 2Y25.23%
EPS Next 3Y20.92%
EPS Next 5Y35.23%
Revenue Next Year22.09%
Revenue Next 2Y13.56%
Revenue Next 3Y18.18%
Revenue Next 5Y22.69%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VLA's earnings are expected to grow with 20.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.23%
EPS Next 3Y20.92%
5. Dividend
5.1 Amount
VLA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VALNEVA SE
EPA:VLA (7/25/2024, 7:00:00 PM)
3.25
-0.03 (-0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap226.12M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.43% | ||
| ROE | -119.91% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 36.83% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)83.19%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y119.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-59.29%
Revenue growth 3Y11.69%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y